… financial statements, the potential exercise of share options and the conversion of preferred shares into ordinary … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. …
… biopharmaceutical company engaged in the discovery and development of RNA-based therapeutics for the treatment of … its Therapeutic Development Network, a network of CF key opinion leaders, as well as to an extensive clinical trial …
… of ProQR. "We have advanced QR-010 through preclinical development and are looking forward to starting the clinical … its Therapeutic Development Network, a network of CF key opinion leaders, as well as to an extensive clinical trial …
… lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology … prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing … related thereto, the continued advancement of our lead development pipeline programs, including ongoing and planned …
… lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology … prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing … related thereto, the continued advancement of our lead development pipeline programs, including ongoing and planned …
Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favora
… Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa The funding will be used for the clinical development of QR-313 Clinical trial in DEB patients to start …
… are no therapies commercially available or in clinical development for this disease. QR-110 has received fast track … granted orphan drug designation in the United States and European Union. Interim safety and efficacy trial results … that the first patient has been dosed in the Phase 1/2 open-label trial assessing the safety, tolerability, …
… ProQR Announces Year End 2025 Operating and Financial Results Advancing AX-0810 through … with target engagement data expected 1H 2026 Selected Development Candidates AX-2402 for Rett syndrome (MECP2, … lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today …